Research Program
Peritoneal fibrosis project

During peritoneal dialysis, continuous exposure to bioincompatible PD solutions and episodes of peritonitis cause inflammation of the peritoneal membrane, which progressively undergoes fibrosis and, ultimately, can lead to ultrafiltration failure (UFF). Recent findings suggest that epithelial-to-mesenchymal transition (EMT) of mesothelial cells (MC) plays a role in the process leading to peritoneal fibrosis. Del Peso et al have found that EMT of MC is the central point in the onset and progression of peritoneal fibrosis associated with PD. EMT is a reversible process and can be manipulated with pharmaceutical products. Thus, therapeutic strategies targeting EMT may be a way to prevent the progression of peritoneal deterioration. However, the member of studies regarding peritoneal fibrosis is very limited, and no biomarker for early detection and intervention of EMT/peritoneal fibrosis has yet been identified.

The goals of this clinical research are:
1.To identify > 1 sensitive and specific biomarker for early diagnosis of peritoneal fibrosis.
2.To determine of the PPARγ agonist can prevent early peritoneal fibrosis.

Future goals: To guide the early diagnosis and early intervention of peritoneal fibrosis.